Novanta (NOVT) Q1 2026 earnings review
Bookings Surge Signals Demand Acceleration, But Dilution Masks Profits
Novanta delivered a strong Q1 top-line beat, with reported revenue growing 10.4% year-over-year. The standout metric is forward-looking: bookings surged 37%, marking the fourth consecutive quarter of accelerating demand and lifting the book-to-bill ratio to 1.10. However, the bottom-line narrative is conflicting. While Adjusted EBITDA expanded a healthy 14%, GAAP Diluted EPS actually fell 14% to $0.51. This drop was driven by a 14% increase in the share count stemming from late 2025's massive equity raise. The core business is accelerating, but management is now on the clock to deploy their $1.5 billion M&A war chest to offset this heavy dilution.
🐂 Bull Case
A 37% surge in bookings strongly validates management's prior claims of a returning upcycle. End markets in AI-driven industrial tech, semiconductor, and minimally invasive surgery are compounding rapidly.
Medical Solutions revenue accelerated significantly, jumping 14.8% YoY to $126.5M. The multi-year strategy to pivot the portfolio toward resilient, high-growth healthcare markets is working.
🐻 Bear Case
Net income was virtually flat YoY ($21.1M vs $21.2M), yet EPS dropped to $0.51 from $0.59. The 5 million additional shares from the recent equity raise will continue to heavily drag on per-share earnings growth until capital is deployed.
Despite higher volumes, Adjusted Gross Margins contracted across both major segments. Automation Enabling Technologies dropped 60 bps to 48.7%, and Medical Solutions dropped 30 bps to 43.4%.
⚖️ Verdict: 🟢
Bullish. The top-line momentum and bookings acceleration are too strong to ignore. While the EPS dilution is a clear near-term headwind, the underlying operational machine is firing on all cylinders and cash flow generation has reversed into high growth.
Key Themes
Bookings Surge De-risks Guidance
The most important data point in this report is the 37% year-over-year growth in bookings, driving a 1.10 book-to-bill ratio. This marks an aggressive, four-quarter accelerating trend (10% -> 17% -> 25% -> 37%). This massive backlog expansion fundamentally de-risks the ambitious Q2 guidance for 6-8% organic revenue growth and indicates that destocking in industrial and medical markets is definitively over.
EPS Dilution Contradicts Profit Growth
A clear contradiction exists between operating profit and shareholder return metrics. Adjusted EBITDA grew 14.2% YoY, but GAAP Diluted EPS reversed, dropping 13.6%. The culprit is the weighted average share count, which ballooned from 36.1 million to 41.2 million shares following the late-2025 equity raise. Until management deploys this capital, operational leverage will fail to reach the bottom line on a per-share basis.
AI and Physical Robotics Entering Upcycle
Macro end-markets are finally providing a tailwind. Management explicitly highlighted building momentum in AI-driven advanced industrial and semiconductor markets. This aligns with prior discussions regarding their sole-supplier status for drilling AI-driven GPU boards and strong penetration into 'Physical AI' applications (warehouse automation and humanoids). The compounding nature of these highly specific technological niches is beginning to reflect in the financials.
Medical Solutions Taking the Lead
The Medical Solutions segment accelerated, jumping 14.8% YoY to $126.5 million. This segment is leveraging the previously announced launches of next-generation smoke-evacuating insufflators and advanced endoscopy pumps. As this segment grows, it shifts the overall corporate profile away from cyclical capital equipment and toward recurring procedural revenues.
Segment Gross Margin Compression
While total corporate Adjusted Gross Profit Margin fell slightly (45.6% vs 46.2%), the segment-level breakdown is mildly concerning. Automation Enabling Technologies contracted from 49.3% to 48.7%, and Medical Solutions slipped from 43.7% to 43.4%. Management needs to clarify if this is due to lingering dual-running costs from site consolidations, product mix shifts, or aggressive pricing to win market share.
M&A Execution Risk Escalates
With the share count bloated and cash reserves sitting on the balance sheet, the pressure to execute M&A is at an all-time high. Management previously touted a $1.5 billion acquisition capacity and the 'largest pipeline' in the CEO's tenure. Every quarter that passes without deploying this capital means shareholders are suffering the dilution without the intended accretive benefits.
Other KPIs
Reversing the cash flow weakness seen in mid-2025, operating cash flow surged 63% YoY. This was driven by a stabilization in net working capital, particularly as inventory buildup related to site transfers and tariff mitigation begins to normalize. Free Cash Flow conversion stands at an exceptional 226% of net income.
Accelerating growth of 14.2% YoY, outpacing the 10.4% revenue growth. Adjusted EBITDA margin expanded to 22.1% (up from 21.4% a year ago), indicating that while gross margins compressed slightly, the company successfully leveraged its operating expenses (R&D was held perfectly flat YoY at $23.2M).
Guidance
Accelerating. The midpoint of $261.5M represents roughly 8.5% reported growth over 25Q2 ($241.0M). More importantly, management specifically guided for 6% to 8% organic revenue growth, a steep acceleration from the 3.1% organic growth delivered in Q1.
Accelerating. Midpoint represents a ~15% YoY increase compared to 25Q2 ($52.2M), implying margin stability to slight expansion.
Stable. The full-year outlook implies roughly 6-7% reported growth over the $981 million generated in 2025. Given the massive backlog generated by the 37% Q1 bookings surge, this guidance appears highly achievable and potentially conservative.
Stable. Implies a full-year margin around 23.6%, up from the 22.1% realized in Q1, requiring excellent operational execution in the back half of the year.
Key Questions
Gross Margin Drivers
Despite 10% revenue growth, Adjusted Gross Margins contracted by 30-60 basis points across both operating segments. Is this compression purely related to the tail-end of manufacturing transfers and dual-running costs, or are there underlying pricing or mix headwinds?
M&A Deployment Timeline
The share count is up 14% year-over-year, which caused Q1 EPS to decline despite EBITDA growing 14%. Given the $1.5B in M&A capacity discussed last quarter, what is the realistic timeline for deploying capital to offset this dilution drag?
Deconstructing the Bookings Surge
Bookings were exceptional at 37% growth. Could management unpack how much of this was driven by specific 'Physical AI' applications (like GPU board drilling or warehouse robotics) versus a broader, normalized recovery in base industrial and medical markets?